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Abstract
We have previously shown that dividing patients with CLL into those with telomeres inside the fusogenic range (TL-IFR)
and outside the fusogenic range (TL-OFR) is powerful prognostic tool. Here, we used a high-throughput version of the assay
(HT-STELA) to establish whether telomere length could predict for outcome to ﬂudarabine, cyclophosphamide, rituximab
(FCR)-based treatment using samples collected from two concurrent phase II studies, ARCTIC and ADMIRE (n= 260). In
univariate analysis, patients with TL-IFR had reduced progression-free survival (PFS) (P < 0.0001; HR= 2.17) and shorter
overall survival (OS) (P= 0.0002; HR= 2.44). Bifurcation of the IGHV-mutated and unmutated subsets according to
telomere length revealed that patients with TL-IFR in each subset had shorter PFS (HR= 4.35 and HR= 1.48, respectively)
and shorter OS (HR= 3.81 and HR= 2.18, respectively). In addition, the OS of the TL-OFR and TL-IFR subsets were not
signiﬁcantly altered by IGHV mutation status (P= 0.61; HR= 1.24 and P= 0.41; HR= 1.47, respectively). In multivariate
modeling, telomere length was the dominant co-variable for PFS (P= 0.0002; HR= 1.85) and OS (P= 0.05; HR= 1.61).
Taken together, our data suggest that HT-STELA is a powerful predictor of outcome to FCR-based treatment and could be
used to inform the design of future risk-adapted clinical trials.
Introduction
The management of chronic lymphocytic leukemia (CLL)
has undergone a dramatic change in the last decade due to
the introduction of effective new therapeutic regimens.
However, despite the demonstrable efﬁcacy of B-cell
receptor signaling antagonists like ibrutinib [1, 2], the
gold standard treatment for ﬁt patients with CLL is still
ﬂudarabine, cyclophosphamide, rituximab (FCR) combi-
nation chemoimmunotherapy [3–7]. However, longer
follow-up studies have shown that not all patients beneﬁt
equally from FCR; IGHV-mutated patients have a sig-
niﬁcantly better overall survival compared to IGHV-
unmutated patients [5, 8–10] and patients with 17p
abnormalities show markedly inferior outcomes with this
regimen [8–10].
We and others have previously shown that telomeres
play a pivotal role in the pathogenic progression and out-
come of CLL, with telomere length analysis providing
independent prognostication in all stages of CLL [11–14].
Using high-resolution telomere length analysis (STELA),
we were able to show that patients with very short, dys-
functional telomeres are prone to chromosome fusion
events; these patients commonly demonstrate increased
genomic complexity [11, 14]. Furthermore, many of the
losses and gains of genetic material observed in these
patients appear to be focused at chromosome-ends and are
consistent with the types of genetic rearrangements that can
occur because of telomere fusion, leading to the initiation of
cycles of anaphase-bridging, breakage, and fusion [15].
Importantly, we have shown previously that telomere length
These authors contributed equally: Duncan M. Baird, Christopher D.
Fegan, Chris Pepper
* Chris Pepper
c.pepper@bsms.ac.uk
1 Division of Cancer & Genetics, Cardiff University, School of
Medicine, Heath Park, Cardiff, UK
2 Section of Experimental Haematology, Leeds Institute of Cancer
and Pathology (LICAP), University of Leeds, Leeds, UK
3 Nufﬁeld Department of Population Health, University of Oxford,
Richard Doll Building, Old Road Campus, Roosevelt Drive,
Oxford OX3 7LF, USA
4 University of Sussex, Brighton and Sussex Medical School,
Brighton, UK
Supplementary information The online version of this article (https://
doi.org/10.1038/s41375-019-0389-9) contains supplementary
material, which is available to authorized users.
12
34
56
78
90
()
;,:
12
34
56
78
90
();
,:
is the strongest determinant of clinical outcome in CLL and
predicts for survival following chemotherapy [16, 17].
Here, we investigated telomere length in the context of
frontline treatment with ﬂudarabine, cyclophosphamide,
rituximab (FCR)-based regimens. We considered whether
telomere length was predictive of clinical outcome, using
high-throughput single telomere length analysis (HT-
STELA), in 275 samples from two concurrent UK trials of
FCR-based treatment, ARCTIC and ADMIRE. We then
compared the predictive power of HT-STELA with the
commonly used prognostic markers: β2 microglobulin (β2M),
ﬂuorescence in situ hybridization (FISH) cytogenetics, CD38
expression, ZAP70 expression and IGHV mutation status.
Materials and methods
All the clinical samples used were taken at study entry and
were obtained from the Bloodwise funded UK CLL Trials
Biobank, University of Liverpool. Of the 260 evaluable
samples for telomere length, 128 were derived from the
ARCTIC trial; 64 patients were randomized to receive stan-
dard dose ﬂudarabine, cyclophosphamide and rituximab
(FCR) and 64 received ﬂudarabine, cyclophosphamide,
mitoxantrone, and mini rituximab (FCM-mini R). One-
hundred thirty-two samples were evaluated from the the
ADMIRE study; 64 patients were randomized to receive
standard dose FCR and 68 received ﬂudarabine, cyclopho-
sphamide, mitoxantrone and rituximab (FCMR). 17p muta-
tion or deletion were exclusion criteria from both of these
studies due to their association with poor outcome following
FCR treatment [18, 19]. However, due to the lag time in
genetic analysis, it was later established that 16 patients with a
17p deletion were enrolled in the trials. The median follow-up
in the combined cohort was 4 years and there were 51 deaths
at the censor point. The demographics of the cohort are
summarized in Table 1. Due to the study inclusion criteria for
ARCTIC and ADMIRE, disease burden was generally high
with a mean absolute lymphocyte count of 87.6 × 106/mL
(range 3.3–547.5). However, to avoid potential measurement
error caused by the presence of non-malignant cell fractions,
telomere length was assessed on DNA extracted from puriﬁed
CD19+ B-cells using a B-cell isolation kit (Miltenyi Biotec)
using an adaptation of chromosome-speciﬁc STELA to allow
for high-throughput analysis (HT-STELA). Brieﬂy, the pre-
viously published STELA protocol [20, 21] was adapted
to use telomere-adjacent primers speciﬁc for the XpYp telo-
mere (XpYpC: 5ʹ-CAGGGACCGGGACAAATAGAC-3ʹ)
and the 7q telomere (7qK1: 5ʹ-GGGCACTGCCTCGCTTT
GA-3ʹ), in triplicate 30 μL PCR reactions each containing 30
ng of genomic DNA. Thermal cycling conditions were: 23
cycles of 94 °C for 20 s, 65 °C for 30 s, and 68 °C for 5 min.
Ampliﬁed fragments were resolved using capillary gel
electrophoresis and mean telomere length determined using
PROSize software (AATI, Ankeny, Iowa, USA). Patients
were bifurcated using the previously determined mean XpYp
telomere length threshold for telomere dysfunction [17],
creating two patient groups: one with telomere lengths equal
or less than the mean of the fusogenic range; inside the
fusogenic range (TL-IFR) and the other with telomere lengths
greater than the mean of the fusogenic range; outside the
Table 1 Summary of patient characteristics for the cohort of 260
patients on which 7q HT-STELA was performed
Parameter Number of patients
ARCTIC 128
FCM-mini R 64
FCR 64
ADMIRE 132
FCMR 68
FCR 64
Median ALC (x106/mL) 87.6
Median time to progression (months) 42.3
Median follow-up (months) 47.2
IGHV-M 106
IGHV-UM 148
ND 6
CD38−( < 20%) 157
CD38+ ( ≥ 20%) 102
ND 1
β2M ( < 3.5 mg/L) 65
β2M (≥3.5 mg/L) 176
ND 19
11q- 50
17p- 16
Other FISH cytogenetics 194
7q telomere analysis
IFR 83
OFR 177
ARCTIC: randomized phase IIB trial of ﬂudarabine, cyclopho-
sphamide and rituximab versus ﬂudarbine, cyclophosphamide, Mitox-
antrone with low-dose rituximab in previously untreated CLL patients
ADMIRE: randomized phase IIB trial of ﬂudarabine, cyclopho-
sphamide and rituximuab versus ﬂudarabine, cyclophosphamide,
mitoxantrone and rituximuab in previously untreated CLL
IGHV-M: mutated IGHV genes; ≥2% deviation from the germline
immunoglobulin sequence
IGHV-UM: unmutated IGHV genes; < 2% deviation from the germline
immunoglobulin sequence
β2M: β2 microglobulin
11q-: mutations or deletions in the long arm of chromosome 11
17p-: mutations or deletions in the short arm of chromosome 17
7q telomere analysis–IFR; ≤ the mean telomere length of the fusogenic
range, OFR outside the mean telomere length of the fusogenic range
ND not determined, ALC absolute lymphocyte count
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fusogenic range (TL-OFR). The numerical threshold that
deﬁned these two groups using XpYp telomere analysis was
subsequently adjusted for the 7q telomere according to the
y=mx+ c regression line generated by plotting XpYp telo-
mere length against 7q telomere length. 7q HT-STELA was
used in preference to XpYp HT-STELA as a larger subset of
CLL samples failed to amplify the XpYp telomere (24/275)
when compared with the 7q telomere (15/275). For con-
sistency, all of the subsequent analyses were carried out on
the data generated using 7q HT-STELA (n= 260). However,
it should be noted that there was a strong correlation between
the telomere lengths at each chromosome end (P < 0.0001;
r2= 0.72). In univariate analyses, all the individual prognostic
markers were considered as categorical variables using
previously established thresholds. In multivariate modeling,
the same parameters were evaluated as both categorical and
continuous variables. The variables included in the model
were age, cytogenetic groups (del 11q and del 17p), IGHV
mutation status, CD38 expression, ZAP70 expression, β2M,
absolute lymphocyte count, telomere length. Statistical ana-
lysis was carried out using Prism 6.0 (Graphpad Software
Inc., La Jolla, CA, USA) and SAS version 9.3 software (SAS
Institute, Cary, NC, USA). Univariate comparisons for
progression-free survival (PFS) and overall survival (OS)
were conducted with the logrank test and displayed as
Kaplan-Meier curves. Multivariate analyses were performed
using a Cox proportional hazard model with forward selec-
tion. In all cases P < 0.05 was considered signiﬁcant.
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Fig. 1 Telomere length
measurements using HT-STELA
and the relationship between
telomere length and other
prognostic markers. HT-STELA
was developed to overcome
some of the technical
complexities of the original
STELA assay and to adapt the
assay to make it suitable for
high-throughput analysis.
a shows the strong correlation
between original STELA and
HT-STELA. b shows the strong
correlation between telomere
length measured using HT-
STELA with probes speciﬁc
for the XpYp and 7q telomeres.
c–f 7q HT-STELA conﬁrmed
that poor prognostic subsets all
had signiﬁcantly shorter
telomere length proﬁles than
their respective good prognosis
counter-parts
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Results
High-throughtput STELA allows for the reliable and
rapid evaluation of telomere length in CLL
Our previously described single molecule STELA assay is
both technically challenging and time consuming making
it unsuitable for the evaluation of large numbers of sam-
ples [11]. To overcome these problems, we developed a
modiﬁcation of the STELA assay to facilitate the high-
throughput evaluation of samples (HT-STELA). Here we
present the ﬁrst evidence that this technique is comparable
to standard STELA and can be used to quickly and reli-
ably predict for outcome following FCR-based therapy in
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Fig. 2 Stratiﬁcation of patients by telomere length predicts for PFS and
OS following FCR-based treatment. Bifurcation of the patient cohort
according to the previously deﬁned telomere length threshold for tel-
omere dysfunction was predictive of (a) PFS and (b) OS. Patients
whose telomere length were ≤ the mean of the fusogenic range (TL-
IFR) showed shorter PFS and OS than those patients with mean tel-
omere length outside of the fusogenic range (TL-OFR). Comparison of
the same cohort based on IGHV mutation status showed that IGHV-
unmutated patients had c a shorter median PFS but no difference in d
OS when compared with IGHV-mutated patients. IGHV-mutated and
IGHV-unmutated groups could be divided according to telomere
length, which identiﬁed distinct subsets in each group with e different
PFS and f different OS
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samples derived from two UK CLL trials, ARCTIC
and ADMIRE [6, 7]. To evaluate the utility of HT-STELA
for the analysis of telomere length in CLL, we undertook
a comparison of both STELA and HT-STELA on 260
patient samples, at two separate chromosome-ends
using primers designed to speciﬁcally amplify the XpYp
and the 7q telomeres. We showed strong concordance
between the STELA and HT-STELA assays; Fig. 1a
shows 7q STELA versus 7q HT-STELA (r2= 0.92, P <
0.0001). In addition, Fig. 1b shows the correlation
between the XpYp telomere length and the 7q telomere
length using HT-STELA (r2= 0.72, P < 0.0001). It is
worthy of note that the variance between the two
chromosome-ends was most apparent in samples with
long telomeres and no sample changed category (TL-IFR,
TL-OFR) as a consequence of measuring a different tel-
omere. Consistent with previous reports [11, 14, 15, 21],
short telomere length was signiﬁcantly associated with
CD38 positivity (P= 0.0002, Fig. 1c) and elevated β2M
(P= 0.038, Fig. 1d), IGHV-unmutated cases (P < 0.0001,
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Fig. 3 The impact of telomere length in IGHV-mutated and IGHV-
unmutated groups. Dividing the IGHV-mutated and IGHV-unmutated
prognostic groups according to telomere length revealed a a signiﬁcant
difference in PFS in the IGHV-mutated group with short telomere
patients having shorter PFS. b Short telomere length in the IGHV-
unmutated group showed a trend towards reduced PFS but this was not
signiﬁcant. In terms of OS, the short telomere subsets in both c IGHV-
mutated and d IGHV-unmutated groups showed signiﬁcantly reduced
survival. The OS of patients with e long telomeres (TL-OFR) and f
short telomeres (TL-IFR) were not signiﬁcantly different regardless of
IGHV mutation status
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Fig. 1e) and high-risk cytogenetic lesions (P < 0.0001,
Fig. 1f).
Telomere length predicts for progression-free and
overall survival
We ﬁrst set out to establish whether telomere length could
predict for outcome to FCR-based therapy in the entire
cohort of samples, regardless of randomization. The cohort
was split according to our previously deﬁned threshold of
telomere dysfunction; telomere lengths equal or less than
the mean of the fusogenic range (TL-IFR) and telomere
lengths greater than the mean of the fusogenic range (TL-
OFR). Patients with TL-IFR showed signiﬁcantly shorter
PFS (P < 0.0001; Fig. 2a) and reduced OS (P= 0.0002;
Fig. 2b). In the same cohort, IGHV mutation status
was predictive of PFS (P= 0.0016; Fig. 2c) but not OS
(P= 0.38; Fig. 2d). Bifurcation of the IGHV-mutated and
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Fig. 4 Comparison of telomere length in patients treated in ADMIRE
and ARCTIC. The mean telomere length were not signiﬁcantly dif-
ferent between patients randomized in a ADMIRE and b ARCTIC
clinical trials. Stratiﬁcation accord to telomere length revealed differ-
ential PFS (c and d) and OS (e and f) in both clinical trials regardless
of randomization
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IGHV-unmutated groups into TL-IFR and TL-OFR subsets
showed that telomere length identiﬁed patients with differ-
ent PFS (Fig. 2e) and different OS (Fig. 2f). Neither CD38
expression (< / > 20%) nor β2M (< / > 3.5 mg/L) expression
were predictive of PFS or OS (Supplementary Fig. 1A–D).
In addition, removal of the 17p deleted/mutated patients
from the analysis (n= 16) did not signiﬁcantly alter the
predictive power of telomere length in terms of PFS and OS
(Supplementary Fig. 2). Although the 7q HT-STELA ana-
lysis was selected for use in this study, XpYp HT-STELA
showed similar predictive power for both PFS and OS
(Supplementary Fig. 3).
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Fig. 5 The impact of telomere length in FCR-treated patients derived
from ADMIRE and ARCTIC. Analysis of the patient cohort treated
with standard dose FCR demonstrated that telomere length was a
strong predictor of a PFS and b OS. Comparison of the effect of IGHV
mutation status in the same cohort showed it was c predictive of PFS
but d was not predictive of OS. Bifurcation of the IGHV-mutated and
IGHV-unmutated groups accord to telomere length again reveals
subsets with distinct e PFS and f OS
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Telomere length identiﬁes differential outcomes in
IGHV-mutated and IGHV-unmutated groups
A number of studies, including the German CLL8 study,
have shown that a proportion of IGHV-mutated patients,
treated with FCR, can achieve long-term remissions [8–10].
Here, we show that patients with IGHV-mutated CLL with
short telomeres (TL-IFR) were more likely to progress
during the follow-up period (P < 0.0001, HR= 4.35;
Fig. 3a) and more likely to succumb to their disease (P=
0.006, HR= 3.81; Fig. 3c) than patients with TL-OFR. In
the IGHV-unmutated group, most patients showed clinical
progression during the follow-up period; the median PFS of
of the TL-IFR subset was 3.7 years versus 4.83 years in the
TL-OFR subset (P= 0.08, HR= 1.48; Fig. 3b). The IGHV-
unmutated TL-IFR subset showed a signiﬁcantly worse OS
when compared with the TL-OFR subset (P= 0.025, HR=
2.18; Fig. 3d). It is of interest that the IGHV-mutated subset
with TL-IFR had a median OS almost one year less than the
IGHV-unmutated subset with TL-IFR (4.49 years versus
5.47 years). Although the number of IGHV-mutated patients
with TL-IFR was relatively small (n= 16), our data sug-
gests that telomere length can identify a subset of “bad risk”
IGHV-mutated patients who do not respond well to FCR.
Furthermore, splitting the cohort into TL-IFR and TL-OFR
subsets was a more powerful determinant of clinical out-
come than IGHV mutation status. Indeed, the OS of patients
with TL-OFR and TL-IFR were not signiﬁcantly different
regardless of IGHV mutation status (Fig. 3e, f respectively).
It is worthy of note that of the 16 “bad risk” IGHV-mutated
patients only 2/16 used the IGHV 3–21 gene. In terms of
other known prognostic factors, 5/16 were 11q-, 2/16 were
17p-, 10/16 were CD38+ and 11/16 had β2M ≥3.5 mg/L.
Telomere length is predictive in both ARCTIC and
ADMIRE regardless of randomization
We next analyzed the effect of telomere length in the
samples derived from the two separate trials and between
the randomization arms of the two studies. We showed that
there was no difference in telomere length between patients
randomized to receive FCR and FCMR in the ADMIRE
study (P= 0.92; Fig. 4a) and those randomized to receive
FCR and FCM-mini R in the ARCTIC study (P= 0.59;
Fig. 4b). In both studies, telomere length analysis was able
to identify subsets of patients with different PFS (Fig. 4c, d)
and different OS (Fig. 4e, f) to the FCR-based treatments
given.
Telomere length is predictive in patients treated
with standard dose FCR
Although we demonstrated that mean telomere length was
not different between the patients randomized within both
ADMIRE and ARCTIC, the published data on the two trials
suggested a randomization effect [6, 7] so we performed a
sub-analysis of the effect of telomere length in all patients
treated with standard dose FCR (n= 136). Patients with
short telomeres who received FCR showed a signiﬁcantly
shorter PFS (P= 0.0014, HR= 2.4; Fig. 5a) and shorter OS
(P= 0.0037, HR= 2.91; Fig. 5b). In the same cohort,
IGHV mutation status was predictive of PFS (P= 0.05,
HR= 1.79; Fig. 5c) but not OS (P= 0.36, HR= 1.47;
Fig. 5d). Once again, telomere length was able to identify a
subset of both IGHV-mutated and IGHV-unmutated cases
with a differential PFS and OS when treated with FCR
(Fig. 5e, f respectively). Consistent with the analysis of the
entire cohort, the IGHV-mutated cases with TL-IFR showed
a shorter median PFS (2.53 years) and a shorter median OS
(4.49 years) than the IGHV-unmutated cases with TL-IFR
(3.61 years and 4.81 years respectively; Supplementary
Fig. 4).
Telomere length is the dominant co-variable in
multivariate analysis
In univariate analysis we have shown that telomere length is
a strong predictor of PFS and OS in FCR-based clinical
trials. However, given the association between short telo-
meres and other high-risk prognostic markers, we next set
out to determine whether telomere length would retain
predictive signiﬁcance in multivariate analysis using a Cox
Table 2A Univariate and
multivariate analysis for time to
progression
Univariate HR
(95% CI)
P-value Multivariate HR
(95% CI)
P-value Straight selection
(no forcing)
B2M 0.99 (0.68–1.47) 0.7 1.03 (0.61–1.72) ** P= 0.98
Lymphocyte count 1.00 (1.00–1.00) 0.07 1.00 (0.998–1.003) ** P= 0.5
IGHV mutation
status
1.90 (1.27–2.73) 0.0016 1.08 (0.64–1.84) ** P= 0.8
Del 11q23 1.49 (0.97–2.27) 0.07 1.56 (0.93–2.56) ** P= 0.14
CD38 1.04 (0.67–1.59) 0.99 1.40 (0.86–2.27) ** P= 0.4
7q TL 2.17 (1.59–3.79) <0.0001 1.79 (1.25–2.56) 0.002 1.85 (1.33–2.28)
P = 0.0002
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proportional hazard model with forward selection. Table 2A
and 2B summarize the univariate and multivariate analysis
for PFS and OS; telomere length was the dominant co-
variable with HR= 1.85 (1.33–2.28) and HR= 1.61 (0.99–
2.63) respectively. Indeed, the inclusion of telomere length
in the model rendered all of the other markers insigniﬁcant
even when the inclusion threshold was reduced to P= 0.1.
The tables show the adjusted P-values for telomere length
when all of the other parameters were forced into the model
and the unadjusted P-values for each parameter without
forcing. In keeping with the previously published data from
the ARCTIC and ADMIRE studies [6, 7], age was not an
independent prognostic factor in either univariate or multi-
variate analysis.
Discussion
It has been previously shown that a proportion of chronic
lymphocytic leukemia (CLL) patients have critically short
telomeres and this is associated with genomic instability and
inferior clinical outcome [11, 14]. Indeed, telomere dys-
function was shown to be the most powerful predictor of
survival in a cohort of 321 Patients with CLL and allowed
the accurate stratiﬁcation of Binet stage A patients into
those with indolent disease and those with poor prognosis
[17]. Furthermore, patients with long telomeres showed
superior prognosis regardless of their IGHV mutation status
CD38 expression, ZAP70 expression or cytogenetic risk
group. In keeping with this ﬁnding, telomere dysfunction
was the dominant variable in multivariate analysis. More
recently we proved that telomere dysfunction predicted for
response to the combination of ﬂudarabine and cyclopho-
sphamide in the UK CLL4 clinical trial [16]. Here, we
describe for the ﬁrst time the utility of a high-throughput
adaptation of single telomere length analysis (HT-STELA),
in 260 evaluable samples derived from the ARCTIC and
ADMIRE clinical trials; both trials evaluated the che-
moimmunotherapy combination of ﬂudarabine, cyclopho-
sphamide, rituximab (FCR) in previously untreated Patients
with CLL.
We showed that HT-STELA could be reliably used to
determine telomere length at two different chromosome-
ends. Our data also conﬁrmed our previous ﬁndings that
telomere length measurement at any chromosome end is a
bellwether of the telomere length of all chromosome-ends in
the absecnce of genetic lesions that lead to the loss of
telomeric material. Shorter telomere length was associated
CD38 positivity, increased β2 microglobulin, IGHV-
unmutated gene sequences and high-risk cytogenetics.
Division of the cohort according to the previously deter-
mined mean telomere length threshold for telomere dys-
function [18] revealed that telomere length is a powerful
predictor of both PFS and OS in patients treated with FCR-
based therapies. In contrast, CD38 expression and β2
microglobulin expression were not predictive and IGHV
mutation status was only predictive of PFS. It remains
unclear why our ﬁndings are somewhat different to the
German CLL8 study in terms of OS but the longer median
follow-up in the CLL8 study (5.9 years versus 4 years) may
be a contributing factor as there appears to be a steepening
in the FCR-treated IGHV-unmutated survival curve after
5 years [8]. In any case, telomere length is able to identify
good risk and bad risk patients in both the IGHV-mutated
and IGHV-unmutated groups (Figs. 2e, f and 3). Further-
more, telomere length appears to identify a subset of IGHV-
mutated cases with a particularly poor response to FCR-
based treatment; these patients had a worse median PFS and
median OS than their IGHV-unmutated counter-parts. Fur-
thermore, the adverse impact of short telomeres could not
Table 2B Univariate and
multivariate analysis for overall
survival
Univariate HR
(95% CI)
P-value Multivariate HR
(95% CI)
P-value Straight selection
(no forcing)
B2M 1.18 (0.62–2.19) 0.63 1.25 (0.69–1.97) ** P= 0.3
Lymphocyte count 0.99 (0.99–1.01) 0.2 0.99 (0.99–1.001) ** P= 0.3
IGHV mutation
status
1.29 (0.73–2.28) 0.38 1.33 (0.65–2.70) ** P= 0.3
Del 11q23 1.05 (0.52–2.10) 0.9 1.09 (0.48–2.43) ** P= 0.7
CD38 status 1.13 (0.65–1.98) 0.66 1.33 (0.63–2.78) ** P= 0.5
7q TL 2.44 (1.49–5.18) 0.0002 1.81 (1.08–3.13) 0.02 1.61 (0.99–2.63)
P= 0.05
β2M: β2 microglobulin expression (≥3.5 mg/L versus < 3.5 mg/L)
IGHV mutation status: IGHV-unmutated versus IGHV-mutated
Del 11q23: patients with deletions in chromosome 11q23 versus those without
CD38: CD38 expression (≥20% expression versus < 20% expression)
7q TL: Telomere length measured at chromosome 7q
** indicates forced into multivariable analysis (i.e., analyses adjusted for these factors)
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be explained by IGHV gene usage (IGHV 3–21) [22] or
high-risk cytogenetic lesions (11q-/17p-). Although this
ﬁnding is potentially important, it would need to be con-
ﬁrmed in a larger study as the number of IGHV-mutated
cases with short telomeres was small (n= 16) when com-
pared with the IGHV-unmutated subset (n= 60). It is of
particular note that telomere length appears to be a critical
determinant of clinical outcome and superseded the prog-
nostic impact of IGHV mutation status in this cohort of
patients (Fig. 3e, f).
Since the samples analyzed in this study were drawn
from two separate clinical trials, ADMIRE and ARCTIC,
we next evaluated the inﬂuence of telomere length in each
trial separately and within each of the respective trial arms.
There was no signiﬁcant difference in mean telomere in
either arm of the trials but telomere length was able to
identify good risk and bad risk groups regardless of ran-
domization (Fig. 4). Subsequent analysis of only the FCR-
treated samples drawn from both trials (n= 136) revealed a
similar picture to the entire cohort analysis. Telomere length
was predictive of PFS and OS and could bifurcate IGHV-
mutated and IGHV-unmutated groups in terms of PFS and
OS (Fig. 5 and Supplementary Fig. 2).
Finally, we undertook multivariate modeling to establish
the predictive hierarchy of the prognostic factors measured in
this study. Using a forward selection model, telomere length
was shown to be the dominant co-variable for both PFS and
OS (Table 2A and B, respectively). The strong correlation
between short telomeres and other poor-risk prognostic tools,
including IGHV mutation status, appeared to render these
markers insigniﬁcant when telomere length was included.
Given the relative speed and simplicity of HT-STELA, our
data suggest that it can reliably identify patients who will
beneﬁt from FCR treatment and those who will not. It remains
to be established whether HT-STELA can also be used to
predict for response to non-chemotherapeutic agents like
ibrutinib but it seems likely that adoption of this predictive
biomarker into clinical trials design could enable rational,
risk-adapted, trials with the aim of treating all patients with
the optimal therapeutic regimen.
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